• Users Online: 836
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2015  |  Volume : 40  |  Issue : 4  |  Page : 159-165

TET2 expression in a cohort of Egyptian acute myeloid leukemia patients


1 Internal Medicine Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt
2 Clinical Genetic Center, Faculty of Medicine, Alexandria University, Alexandria, Egypt
3 Clinical Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt

Correspondence Address:
Mona W Ayad
Clinical Pathology Department, Alexandria Medical Faculty, Alexandria University, Alexandria
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1110-1067.170194

Rights and Permissions

Ten-eleven translocation 2 gene (TET2) expression plays a crucial role in DNA methylation and hematopoietic stem cell functions. The prognostic relevance of the TET2 mutation in cytogenetically normal acute myeloid leukemia (AML) patients is still not well established. The aim of the present study was to determine the level of TET2 expression in AML patients, its prognostic significance, and its relation to cytogenetics. We studied TET2 gene expression by real-time PCR in 33 AML patients and 34 healthy controls matched for age and sex. The median age of AML patients at presentation was 40 years, with a female to male ratio of 1.06 : 1. A total of 87.9% were de-novo AML and 12.1% were chronic myeloid leukemia in blastic crisis. In all, 66.6% of cases had normal cytogenetics. Underexpression of the TET2 gene was present in 90.6% (0.3098 ± 0.3846) of the patients. TET2 expression was not affected by age (P = 0.609) or cytogenetic findings (P = 0.057). Yet, it was correlated inversely with pretreatment white blood cell count (rs = −0.366, P = 0.04). It also correlated with lower remission rates (P = 0.002) and relapse (P = 0.000). TET2 probably plays a role in the pathogenesis and progression of AML. This can play a role in targeted therapy in the future. Further studies are recommended to assess TET2 expression in response to hypomethylating agents to determine its predictive role in response to therapy using these agents.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1212    
    Printed29    
    Emailed0    
    PDF Downloaded1110    
    Comments [Add]    

Recommend this journal